{"id":71446,"date":"2026-05-20T11:50:00","date_gmt":"2026-05-20T11:50:00","guid":{"rendered":"https:\/\/medsbase.com\/aod-9604\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"aod-9604","status":"publish","type":"product","link":"https:\/\/medsbase.com\/it\/product\/aod-9604\/","title":{"rendered":"AOD-9604 (Farmaco Anti-Obesit\u00e0 9604 \/ Tyr-hGH 177-191)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Risposta rapida \u2014 Cos'\u00e8 l'AOD-9604?<\/h3>\n<p style=\"margin: 0;\"><strong>AOD-9604<\/strong> (\u201cAnti-Obesity Drug 9604\u201d, CAS 221231-10-3) \u00e8 un peptide sintetico di 16 aminoacidi sviluppato da <strong>Metabolic Pharmaceuticals Ltd<\/strong> (Australia) alla fine degli anni '90 come analogo stabilizzato del frammento lipolitico C-terminale dell'ormone della crescita umano. Sequenza Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 aa, con un'estensione N-terminale di tirosina che stabilizza il frammento parentale hGH 177\u2013191, e un ponte disolfuro intramolecolare Cys7\u2013Cys14). Formula molecolare C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>, MW 1815.1 Da. In published in-vitro and rodent studies AOD-9604 retains the <strong>attivit\u00e0 lipolitica e anti-lipogenica<\/strong> della molecola hGH parentale ma non si <em>not<\/em> bind the GH receptor \u2014 so it does not induce IGF-1, does not activate growth-axis JAK2\/STAT5 signalling, and does not produce the growth-promoting effects of full-length HGH. Failed Phase IIb obesity trial (2007); now used as a pharmaceutical-grade peptide. <em>For clinical studies use only.<\/em><\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Cosa ottieni con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/it\/reviews\/\">recensioni dei clienti<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ogni ordine \u00e8 coperto dalla nostra <a href=\"https:\/\/medsbase.com\/it\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica di Garanzia di Rispedizione<\/strong><\/a> \u2014 se il tuo pacco non arriva entro 20 giorni lavorativi, lo rispediamo.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifiche<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Dettaglio<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Classe di Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Synthetic 16-amino-acid peptide; stabilised C-terminal hGH-fragment analogue; lipolytic \/ anti-lipogenic peptide (decoupled from GH-receptor binding)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nome Chimico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">AOD-9604 (\u201cFarmaco Anti-Obesit\u00e0 9604\u201d; sinonimi: Tyr-hGH 177-191; H-Tyr-(frammento 177-191 hGH)-OH)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Numero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">221231-10-3 (riferimento canonico Sigma-Aldrich, MedKoo, ChemicalBook)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formula Molecolare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecolare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1815.1 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequenza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (codice a lettera singola: YLRIVQCRSVEGSCGF; 16 amminoacidi). Il ponte disolfuro intramolecolare Cys7\u2013Cys14 forma una struttura ciclica che mima la geometria del disolfuro della regione parentale hGH 182\u2013189. La tirosina N-terminale \u00e8 un'aggiunta sintetica (non presente nell'hGH nativo 177\u2013191) che stabilizza il frammento contro la degradazione proteolitica ammino-terminale.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Meccanismo d'azione<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Lipolisi meccanicamente disaccoppiata<\/strong>. AOD-9604 NON si lega al recettore GH (GHR) \u2014 la superficie di legame del GHR nell'hGH nativo risiede nella porzione N-terminale (regione residui 1\u2013120), assente nel frammento 176\u2013191. L'attivit\u00e0 lipolitica\/anti-lipogenica si ritiene sia mediata dalla segnalazione del recettore \u03b23-adrenergico e dall'attivazione diretta della lipasi ormono-sensibile (HSL) degli adipociti via cAMP-PKA. Il meccanismo rimane incompletamente caratterizzato nella letteratura pubblicata \u2014 non esiste un singolo recettore confermato per il frammento lipolitico C-terminale.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Emivita plasmatica<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4 minuti (molto breve \u2014 determinato dalla troncatura proteolitica N-terminale nonostante la tirosina stabilizzante). Questa breve emivita \u00e8 una delle principali ipotesi per cui lo studio di fase IIb sull'obesit\u00e0 (2007) non ha raggiunto gli endpoint di perdita di peso \u2014 il frammento viene degradato prima che possa accumularsi un'esposizione recettoriale sufficiente nel tessuto target.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Purezza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificato con HPLC); spettrometria di massa MALDI-TOF conferma 1815.1 Da. COA disponibile su richiesta.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e0<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Solubile in acqua batteriostatica, acqua sterile, PBS e acido acetico 0.1% a \u22655 mg\/mL; facilmente solubile in DMSO a \u226550 mg\/mL per la preparazione di stock in vitro. Il ponte disolfuro Cys7\u2013Cys14 vincola la geometria del peptide ma non impedisce la solubilit\u00e0 acquosa.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Conservazione<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizzato: 2\u20138 \u00b0C non aperto per scorte di lavoro a breve termine; \u221220 \u00b0C per conservazione a lungo termine (stabile \u226536 mesi a \u221220 \u00b0C; \u226518 mesi a 2\u20138 \u00b0C). Soluzione acquosa ricostituita: 2\u20138 \u00b0C, utilizzare entro ~30 giorni. Proteggere dalla luce. Evitare ripetuti cicli di congelamento-scongelamento della soluzione ricostituita \u2014 il ponte disolfuro \u00e8 stabile a un singolo ciclo di congelamento-scongelamento, ma cicli cumulativi rischiano la formazione di tioli liberi e aggregazione parziale.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Cos'\u00e8 AOD-9604?<\/h2>\n<p><strong>AOD-9604<\/strong> (\u201cAnti-Obesity Drug 9604\u201d; CAS 221231-10-3) \u00e8 un peptide sintetico di 16 aminoacidi sviluppato da <strong>Metabolic Pharmaceuticals Ltd<\/strong> presso la Monash University a Melbourne, Australia, a partire dalla fine degli anni '90. \u00c8 un analogo stabilizzato del frammento lipolitico C-terminale dell'ormone della crescita umano nativo (residui 177\u2013191), al quale \u00e8 stata aggiunta una tirosina N-terminale per rallentare la degradazione proteolitica amino-terminale. Sequenza Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF), con il ponte disolfuro intramolecolare Cys182\u2013Cys189 del parentale hGH preservato come Cys7\u2013Cys14 nella numerazione del frammento. Peso molecolare 1815.1 g\/mol, formula empirica C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>. The pharmacological logic behind AOD-9604 is one of the cleanest examples of structure-function dissection in HGH peptide studies. Native full-length human growth hormone (191 amino acids) has at least two distinct biological activities: <strong>effetti anabolici\/promuoventi la crescita<\/strong> (mediati attraverso il recettore GH, segnalazione JAK2\/STAT5 e produzione a valle di IGF-1) e <strong>effetti lipolitici\/anti-lipogenici<\/strong> (mediated through a separate, incompletely-characterised mechanism that does not require GH-receptor engagement). The Monash group&#8217;s hypothesis was that the lipolytic activity is encoded in the C-terminal region of the molecule \u2014 and that a synthetic peptide encompassing just that region might retain the fat-mobilising activity while losing the growth-axis-engaging activity. This proved correct in published in-vitro and rodent studies: the 176\u2013191 fragment retains lipolytic and anti-lipogenic activity in adipocyte culture and DIO mouse models, but does not bind GHR, does not activate JAK2\/STAT5, and does not induce IGF-1. AOD-9604 progressed through multiple Phase I and Phase II clinical trials in the early-to-mid 2000s, culminating in a 28-week Phase IIb obesity trial (~500 patients) completed in 2007 by Metabolic Pharmaceuticals. The trial did not achieve its primary weight-loss endpoint, and the obesity-pharmacology development programme was discontinued. AOD-9604 subsequently entered the studies-peptide and unregulated-supplement markets, where it has remained one of the most-cited &#8220;fat-loss peptides&#8221; in non-clinical literature. The compound retains studies utility as the canonical pharmacological tool for studying GHR-decoupled lipolysis, the C-terminal hGH fragment biology, and the structure-function basis of HGH&#8217;s multiple activities. A note on nomenclature: AOD-9604 and &#8220;<a href=\"https:\/\/medsbase.com\/it\/hgh-fragment-176-191\/\">Frammento HGH 176-191<\/a>&#8221; are often used interchangeably in the supplier and studies-peptide marketplace. Strictly, AOD-9604 (CAS 221231-10-3) is the Metabolic-Pharmaceuticals-developed analogue with the N-terminal Tyr stabilisation. &#8220;HGH Fragment 176-191&#8221; (CAS 66004-57-7 per some references) is the older, un-stabilised hGH 177\u2013191 fragment that AOD-9604 was derived from. Both share the same YLRIVQCRSVEGSCGF amino-acid sequence in many supplier preparations \u2014 but the AOD-9604 designation specifically identifies the registered Metabolic-Pharmaceuticals compound. Users should consult the COA to confirm which form a given supplier batch corresponds to. <\/p>\n<h2>Meccanismo d'Azione \u2014 Lipolisi Disaccoppiata da GHR<\/h2>\n<p>AOD-9604&#8217;s mechanism is among the most-discussed in HGH peptide studies:<\/p>\n<ul>\n<li><strong>Assenza di legame al recettore GH<\/strong> \u2014 La superficie di legame del GHR dell'hGH nativo \u00e8 contenuta nella met\u00e0 N-terminale della molecola (regione dei residui 1-120), assente nel frammento AOD-9604\/176-191. Di conseguenza, l'AOD-9604 NON si lega al recettore dell'ormone della crescita (GHR), NON attiva la segnalazione JAK2\/STAT5, NON induce la produzione epatica di IGF-1 e NON produce gli effetti promuoventi la crescita, stimolanti i condrociti o contro-regolatori dell'insulina della molecola <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a> originaria. Questa \u00e8 la propriet\u00e0 <em>negativa<\/em> pharmacological property and the basis for AOD-9604&#8217;s studies utility as a lipolysis-axis-isolating tool.<\/li>\n<li><strong>segnalazione del recettore \u03b23-adrenergico (ipotesi)<\/strong> \u2014 The leading mechanistic hypothesis for AOD-9604&#8217;s lipolytic activity is that it engages the \u03b23-adrenergic receptor (ADRB3) on adipocytes, either directly as an allosteric modulator or via an intermediate pathway. Published in-vitro has demonstrated that AOD-9604&#8217;s lipolytic effect is blunted by \u03b23-adrenergic antagonists, supporting the \u03b23-AR hypothesis, although direct AOD-9604 \/ \u03b23-AR binding has not been conclusively demonstrated in radioligand-binding assays. The mechanism remains incompletely characterised \u2014 a feature users should be aware of when interpreting published AOD-9604 results.<\/li>\n<li><strong>Attivazione dell'ormone-sensibile lipasi (HSL)<\/strong> \u2014 A valle dell'interazione con il recettore, \u00e8 stato riportato che l'AOD-9604 attiva l'ormone-sensibile lipasi degli adipociti tramite fosforilazione mediata da PKA (la via canonica di attivazione della lipolisi), promuovendo l'idrolisi dei trigliceridi in glicerolo e acidi grassi liberi. L'aumento del rilascio di acidi grassi liberi in circolo \u00e8 stato documentato in studi in vivo su roditori pubblicati dopo somministrazione di AOD-9604.<\/li>\n<li><strong>Attivit\u00e0 anti-lipogenica<\/strong> \u2014 Oltre a promuovere la lipolisi, \u00e8 stato riportato che l'AOD-9604 sopprime la lipogenesi de novo negli adipociti coltivati \u2014 riducendo l'attivit\u00e0 dell'acetil-CoA carbossilasi (ACC) e della sintasi degli acidi grassi (FAS) nei saggi di differenziazione 3T3-L1. Il profilo combinato di aumento della lipolisi\/diminuzione della lipogenesi \u00e8 la farmacologia canonica di \u201cmobilizzazione dei grassi\u201d che il programma originale Metabolic-Pharmaceuticals era progettato per attivare.<\/li>\n<li><strong>Cartilage \/ osteoarthritis studies (secondary indication)<\/strong> \u2014 Following the failure of the obesity programme, AOD-9604 was repositioned for evaluation in osteoarthritis studies, with the hypothesis that chondroprotective effects of the parent hGH might be partially retained in the C-terminal fragment. Published in-vitro and small-animal has reported chondrocyte-protective effects, although no large clinical trial in this indication has been completed.<\/li>\n<li><strong>Il problema dell'emivita di 4 minuti<\/strong> \u2014 AOD-9604&#8217;s plasma half-life is approximately 4 minutes, driven by rapid amino-terminal proteolytic truncation despite the N-terminal Tyr stabilisation. This very short pharmacokinetic profile is one of the leading hypotheses for why the Phase IIb obesity trial did not achieve weight-loss endpoints \u2014 the fragment is degraded before sufficient receptor exposure can accumulate in target adipose tissue under once-daily SC dosing. Newer peptides that target the same lipolysis-axis biology with longer half-lives (modified hGH fragments with PEG-stabilisation, fragment-Fc fusion proteins) are in earlier-stage studies and not commercially available.<\/li>\n<\/ul>\n<p>The combination of mechanistically clean GHR-decoupling and disappointing in-vivo half-life makes AOD-9604 a useful tool with a clear pharmacological story but a documented translational limitation. Published studies dosing in rodents is typically 100\u20131,000 \u00b5g\/kg\/d SC, with the higher end of this range used to overcome the short half-life by saturating clearance. In cell-culture work, micromolar concentrations are used because of the short biological half-life of the fragment in culture medium. <\/p>\n<h2>Published Evidence<\/h2>\n<p>AOD-9604 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacologia della lipolisi disaccoppiata dal GHR<\/strong> \u2014 the canonical tool for studying the lipolytic \/ anti-lipogenic activity of the C-terminal hGH fragment in isolation from GH-axis signalling; standard reference compound for any new &#8220;fat-loss-only&#8221; hGH-fragment studies<\/li>\n<li><strong>Structure-function studies of HGH<\/strong> \u2014 AOD-9604 is one of the cleanest examples of pharmacological structure-function dissection of the multi-activity HGH molecule; used in published studies that maps the lipolytic-domain residues of native HGH<\/li>\n<li><strong>Adipocyte biology and lipolysis studies<\/strong> \u2014 drives lipolysis in cultured 3T3-L1 and primary adipocyte preparations; used in studies on the regulation of adipocyte hormone-sensitive lipase, lipid droplet remodelling, and brown \/ beige adipocyte biology<\/li>\n<li><strong>Farmacologia del recettore \u03b23-adrenergico (indiretta)<\/strong> \u2014 AOD-9604&#8217;s \u03b23-AR-dependence (in some published studies) makes it useful as an indirect probe of \u03b23-AR-coupled lipolysis pathways, alongside direct \u03b23-AR agonists (CL-316,243, mirabegron)<\/li>\n<li><strong>Diet-induced obesity (DIO) rodent studies<\/strong> \u2014 published 4\u20138 week dosing protocols (100\u20131,000 \u00b5g\/kg\/d SC) in DIO mice and rats have been reported to reduce fat-mass without affecting lean-mass or IGF-1 levels; standard tool for the &#8220;lipolytic-only&#8221; component of fat-loss pharmacology<\/li>\n<li><strong>Cartilage \/ chondrocyte studies<\/strong> \u2014 used in published in-vitro chondrocyte and small-animal osteoarthritis models for chondroprotective evaluation; secondary studies indication following the discontinuation of the obesity programme<\/li>\n<li><strong>Farmacologia comparativa vs HGH 191AA e Frammento HGH 176-191<\/strong> \u2014 confronti testa a testa pubblicati di AOD-9604 vs HGH a lunghezza intera e il frammento non stabilizzato 176-191 hanno caratterizzato i profili differenziali di legame al GHR, induzione di IGF-1 e lipolitici; AOD-9604 si colloca all'estremo \u201csolo lipolitico, nessun asse di crescita\u201d di questo spettro<\/li>\n<li><strong>Plasma-stability and protease-resistance studies<\/strong> \u2014 the 4-minute half-life makes AOD-9604 a useful reference compound for protease-resistance studies; newer modified analogues (PEG-stabilised, fragment-Fc fusion, alternative N-terminal cap modifications) are benchmarked against AOD-9604 in early-stage development studies<\/li>\n<\/ul>\n<p>For broader context on HGH-axis and fat-loss peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/it\/hgh-fragment-176-191\/\">Frammento HGH 176-191<\/a> (il frammento genitore non stabilizzato \u2014 confronto diretto), <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a> (la molecola genitore a lunghezza intera \u2014 per farmacologia comparativa), <a href=\"https:\/\/medsbase.com\/it\/tesamorelin\/\">Tesamorelin<\/a> (analogo GHRH \u2014 stimolazione dell'asse HGH a monte), <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a> (analogo GHRH 1-29), e <a href=\"https:\/\/medsbase.com\/it\/mots-c\/\">MOTS-c<\/a> (peptide metabolico derivato dai mitocondri). Esplora l'intero <a href=\"https:\/\/medsbase.com\/it\/peptides\/\">peptides &amp; compounds catalog<\/a>, o consulta il <a href=\"https:\/\/medsbase.com\/it\/best-peptides-for-fat-loss\/\">fat-loss peptides<\/a> e <a href=\"https:\/\/medsbase.com\/it\/best-growth-hormone-peptides\/\">growth-hormone peptides<\/a> hubs. <\/p>\n<h2>Concentrazioni e Dosaggi Disponibili<\/h2>\n<p>MedsBase stocks AOD-9604 in three lyophilized vial sizes calibrated to typical in-vitro and in-vivo protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosaggio per Flaconcino<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso d'Uso Tipico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dimensioni della Confezione<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>2 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Coltura cellulare in vitro e titolazione in vivo a breve termine \u2014 saggi di lipolisi su adipociti 3T3-L1, farmacologia degli adipociti primari, pannelli dose-risposta, titolazione murina a singola coorte<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard mid-strength \u2014 diet-induced obesity rodent protocols (100\u2013500 \u00b5g\/kg\/d SC for 4\u20138 weeks), chondrocyte \/ osteoarthritis studies, multi-cohort sample sizes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-strength vial \u2014 extended-cycle \/ high-dose protocols (up to 1 mg\/kg\/d SC), large-cohort DIO studies, multi-arm structure-function comparisons; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical entity (lyophilized AOD-9604, \u226599% HPLC purity, MALDI-TOF mass-confirmed at 1815.1 Da). The 10\u00a0mg vial provides the lowest per-mg cost for large in-vivo protocols (a single 10\u00a0mg vial supports approximately 50 days of 200 \u00b5g\/kg\/d dosing in a 25-g mouse, or about 10 days at 1\u00a0mg\/kg\/d in a 30-g rat). Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Come si confronta \u2014 AOD-9604 vs Frammento HGH 176-191<\/h2>\n<p>AOD-9604 e <a href=\"https:\/\/medsbase.com\/it\/hgh-fragment-176-191\/\">Frammento HGH 176-191<\/a> are the two HGH C-terminal fragment peptides in this catalogue, and they sit very close together on the structure-function spectrum. AOD-9604 is the Metabolic-Pharmaceuticals-developed analogue with the N-terminal tyrosine extension that adds protease-stability. The un-stabilised HGH Fragment 176-191 lacks the N-terminal Tyr and has a slightly shorter half-life in culture \/ in-vivo, but is otherwise mechanistically identical. The two compounds are often used interchangeably in supplier listings \u2014 the differentiation matters for rigorous pharmacology studies, less so for cell-culture stimulation work. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">AOD-9604<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Frammento HGH 176-191<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Numero CAS<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">221231-10-3<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">66004-57-7<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Sequenza (lettera singola)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">YLRIVQCRSVEGSCGF (16 aa; con stabilizzazione N-terminale Tyr)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">YLRIVQCRSVEGSCGF (16 aa) o LRIVQCRSVEGSCGF (15 aa, non stabilizzato) a seconda del lotto del fornitore; consultare il COA<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecolare<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1815.1 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1817.06 g\/mol (16-aa grado fornitore) o 1654 g\/mol (15-aa non stabilizzato)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Origine<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Metabolic Pharmaceuticals Ltd (Monash University, Australia, fine anni '90)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Earlier academic studies-peptide preparation, pre-dating AOD-9604<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Emivita plasmatica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~4 minuti<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2\u20133 minuti (pi\u00f9 breve, meno stabile alla proteasi)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Legame al recettore GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nessuno \u2014 non coinvolge l'asse GHR \/ JAK2 \/ STAT5 \/ IGF-1<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nessuno \u2014 stessa propriet\u00e0; entrambi sono frammenti disaccoppiati da GHR<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Storia degli studi clinici<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Lo studio di fase IIb sull'obesit\u00e0 (~500 pazienti, 2007) non ha raggiunto l'endpoint primario; programma interrotto<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nessun programma formale di sviluppo clinico<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best applications<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Leggermente preferibile per il lavoro in vivo grazie all'emivita leggermente pi\u00f9 lunga; composto di riferimento per i confronti struttura-funzione<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Saggi di lipolisi in colture cellulari in vitro dove l'emivita breve \u00e8 meno limitante<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on rigorous structure-function HGH-fragment pharmacology, AOD-9604 with its registered CAS \/ known origin is the cleaner reference. For exploratory in-vitro lipolysis work where the precise origin matters less, <a href=\"https:\/\/medsbase.com\/it\/hgh-fragment-176-191\/\">Frammento HGH 176-191<\/a> is the more economical option. For studies that needs the full HGH pharmacology including GH-receptor \/ IGF-1 axis engagement, see <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a>. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Hai bisogno di acqua BAC?<\/strong> La ricostituzione di qualsiasi flaconcino liofilizzato richiede acqua sterile batteriostatica. Abbina questo prodotto al nostro <a href=\"\/it\/bac-water\/\"><strong>BAC Water (Acqua Batteriostatica)<\/strong><\/a> \u2014 flaconcino multidose da 30 mL, conservato con alcool benzilico 0,9%, grado USP.<\/div>\n<h2>Conservazione e ricostituzione<\/h2>\n<p><strong>Prima della ricostituzione:<\/strong> conservare i flaconcini liofilizzati refrigerati a 2\u20138 \u00b0C nella confezione originale per lo stock di lavoro a breve termine. Per lo stoccaggio a lungo termine, congelare i flaconcini non aperti a \u221220 \u00b0C (stabile \u226536 mesi a \u221220 \u00b0C; \u226518 mesi a 2\u20138 \u00b0C). Il ponte disolfuro Cys7\u2013Cys14 \u00e8 stabile nello stato liofilizzato e durante la conservazione refrigerata breve. Proteggere dalla luce. <strong>Procedura di ricostituzione:<\/strong> Iniettare acqua batteriostatica lungo la parete laterale del flaconcino (non direttamente sul panetto liofilizzato). Per un flaconcino da 2 mg, 1,0 mL di diluente produce una soluzione di lavoro a 2 mg\/mL; 0,5 mL produce 4 mg\/mL. Per un flaconcino da 5 mg, 1,0 mL produce 5 mg\/mL; 2,5 mL produce 2 mg\/mL. Per un flaconcino da 10 mg, 1,0 mL produce 10 mg\/mL (il limite pratico di solubilit\u00e0 in tampone acquoso); 5,0 mL produce 2 mg\/mL. L'AOD-9604 si scioglie rapidamente con un leggero agitamento a temperatura ambiente \u2014 tipicamente entro 15-30 secondi. Una volta ricostituito, conservare il flaconcino a 2-8 \u00b0C e utilizzare entro 30 giorni. Proteggere dalla luce. <strong>Evitare ripetuti cicli di congelamento-scongelamento del materiale ricostituito<\/strong> \u2014 il congelamento-scongelamento cumulativo rischia di causare disordine del legame disolfuro Cys7\u2013Cys14 e aggregazione parziale. Scartare se compaiono torbidit\u00e0, particelle o un marcato cambiamento di colore. <\/p>\n<h2>Domande frequenti<\/h2>\n<h3>Qual \u00e8 la differenza tra AOD-9604 e HGH Fragment 176-191?<\/h3>\n<p>AOD-9604 (CAS 221231-10-3) is the Metabolic-Pharmaceuticals-developed registered compound with an N-terminal tyrosine extension that adds amino-terminal protease-stability to the parent hGH 177\u2013191 fragment. &#8220;<a href=\"https:\/\/medsbase.com\/it\/hgh-fragment-176-191\/\">Frammento HGH 176-191<\/a>&#8221; (CAS 66004-57-7 per some references) is the earlier, un-stabilised version of the same C-terminal hGH peptide. The two are often used interchangeably in the studies-peptide marketplace, but strictly the AOD-9604 designation identifies the Metabolic-Pharmaceuticals registered analogue with the stabilising Tyr. Both lack GHR binding and both retain the lipolytic activity of the parent hGH C-terminal region. Consult the COA to confirm which sequence form a given batch corresponds to. <\/p>\n<h3>No. L'AOD-9604 \u00e8 un frammento sintetico di 16 aminoacidi dell'HGH che copre solo la regione lipolitica C-terminale (residui 176\u2013191 + tirosina N-terminale). L'HGH nativo \u00e8 la proteina completa di 191 aminoacidi. La differenza farmacologica pi\u00f9 importante \u00e8 che l'HGH a lunghezza completa si lega al recettore dell'ormone della crescita (GHR) e attiva l'asse JAK2\/STAT5\/IGF-1 \u2014 guidando gli ampi effetti promuoventi la crescita e metabolici dell'HGH \u2014 mentre l'AOD-9604 NON si lega al GHR e NON induce IGF-1. L'AOD-9604 conserva solo l'attivit\u00e0 lipolitica\/anti-lipogenica della molecola parentale. I due composti sono quindi meccanicamente distinti: HGH 191AA per la farmacologia completa dell'asse GH, AOD-9604 per la ricerca solo sulla lipolisi.<\/h3>\n<p>No. AOD-9604 \u00e8 un frammento sintetico di 16 aminoacidi dell'HGH che copre solo la regione lipolitica C-terminale (residui 176\u2013191 + Tyr N-terminale). Nativo <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a> is the full-length 191-amino-acid protein. The most important pharmacological difference is that full-length HGH binds the growth hormone receptor (GHR) and activates the JAK2\/STAT5\/IGF-1 axis \u2014 driving the broad growth-promoting and metabolic effects of HGH \u2014 while AOD-9604 does NOT bind GHR and does NOT induce IGF-1. AOD-9604 retains only the lipolytic \/ anti-lipogenic activity of the parent molecule. The two compounds are therefore mechanistically distinct: HGH 191AA for full GH-axis pharmacology, AOD-9604 for lipolysis-only studies. <\/p>\n<h3>Perch\u00e9 il trial di fase IIb sull'obesit\u00e0 ha fallito?<\/h3>\n<p>The 28-week Phase IIb obesity trial (~500 patients, completed by Metabolic Pharmaceuticals in 2007) did not achieve its primary weight-loss endpoint relative to placebo. The leading hypotheses in subsequent published analyses are: (1) the very short plasma half-life (~4 minutes) limits cumulative receptor exposure under once-daily SC dosing; (2) the lipolytic effect, while real in mechanistic in-vitro and acute in-vivo experiments, may not translate to net adipose-mass loss in the human metabolic context where compensatory anti-lipolytic signalling dominates over chronic dosing; (3) the in-vivo dose may have been insufficient to overcome the pharmacokinetic constraint. The compound was repositioned for osteoarthritis studies after the obesity programme was discontinued. <\/p>\n<h3>What published dose ranges have been used in rodent studies?<\/h3>\n<p>Published mouse and rat in-vivo protocols typically use 100\u20131,000 \u00b5g\/kg\/d SC, with most published work in the 200\u2013500 \u00b5g\/kg\/d range for 4\u20138 weeks. The higher end of this range (up to 1 mg\/kg\/d) has been used in some publications to overcome the short half-life. In-vitro 3T3-L1 adipocyte assays typically use 1\u201310 \u00b5M. Users should consult primary literature (Ng et\u00a0al. \u2014 Metabolic Pharmaceuticals studies; Heffernan et\u00a0al. \u2014 adipocyte mechanism studies) for species-, model-, and endpoint-specific guidance. <\/p>\n<h3>Qual \u00e8 lo status normativo WADA di AOD-9604?<\/h3>\n<p>AOD-9604 is not on the current WADA Prohibited List under its specific name. However, the broader S2 class (Peptide Hormones, Growth Factors, Related Substances and Mimetics) explicitly covers growth-hormone fragments and &#8220;GH-axis-related compounds,&#8221; and AOD-9604&#8217;s classification under this broader category has been the subject of regulatory discussion. Users conducting human-subject studies with AOD-9604 should consult the current WADA Prohibited List and applicable jurisdictional regulations directly rather than relying on the absence of a specific name from the list. <\/p>\n<h3>Qual \u00e8 la differenza tra AOD-9604 e gli agonisti \u03b23-adrenergici diretti come il mirabegron?<\/h3>\n<p>Mirabegron e CL-316,243 sono <em>diretto<\/em> agonisti del recettore \u03b23-adrenergico \u2014 piccole molecole che si legano al sito ortosterico del \u03b23-AR e attivano la segnalazione Gs-cAMP. AOD-9604 \u00e8 un <em>indiretto<\/em> \u03b23-AR engager (in some published studies) \u2014 the lipolytic activity is blunted by \u03b23-AR antagonists, supporting \u03b23-AR-dependence, but direct AOD-9604 \/ \u03b23-AR binding has not been conclusively demonstrated. For studies that needs cleanly defined direct \u03b23-AR pharmacology, mirabegron or CL-316,243 are the preferred tools. For studies that needs the broader &#8220;lipolytic-fragment-of-HGH&#8221; pharmacology with its incompletely-characterised mechanism, AOD-9604 is the canonical reference. <\/p>\n<h3>Can AOD-9604 be combined with HGH 191AA, GHRH analogues, or other lipolytic peptides in protocols?<\/h3>\n<p>S\u00ec \u2014 AOD-9604 agisce su un livello diverso della biologia dell'asse HGH rispetto alla forma a lunghezza intera <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a> o agli analoghi del GHRH (<a href=\"https:\/\/medsbase.com\/it\/tesamorelin\/\">Tesamorelin<\/a>, <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a>), and combinations are commonly used in published studies to dissect lipolytic-only contributions from broader GH-axis effects. The most-published combinations are AOD-9604 + HGH 191AA (testing whether the lipolytic component adds to or substracts from full HGH activity); AOD-9604 + <a href=\"https:\/\/medsbase.com\/it\/mots-c\/\">MOTS-c<\/a> (dual fat-loss studies, different mechanisms); AOD-9604 + a GHRH analogue (testing whether endogenous-pulsatile HGH release combined with the lipolytic fragment outperforms either alone). Reconstitute each separately and follow each compound&#8217;s specific storage rules. <\/p>\n<h3>Perch\u00e9 AOD-9604 \u00e8 talvolta indicato come 1815.1 Da e talvolta come 1817 Da?<\/h3>\n<p>La discrepanza riflette la differenza tra massa monoisotopica (1815.1 Da, calcolata dall'isotopo pi\u00f9 abbondante di ogni atomo) e massa molecolare media (1817.1 Da, calcolata dalla massa media ponderata degli isotopi naturali di ogni atomo). Entrambe sono corrette per la stessa molecola. La spettrometria di massa MALDI-TOF tipicamente riporta la massa monoisotopica per peptidi di queste dimensioni; la letteratura pi\u00f9 vecchia e alcuni fornitori riportano la massa media. Per scopi di COA, il valore di 1815.1 Da \u00e8 il riferimento canonico Sigma-Aldrich. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for HGH-Axis and Fat-Loss Studies<\/h2>\n<ul>\n<li><a href=\"\/it\/hgh-fragment-176-191\/\"><strong>Frammento HGH 176-191<\/strong><\/a> \u2014 Frammento genitore non stabilizzato \u2014 fratello meccanicistico diretto, lipolisi simile disaccoppiata dal GHR<\/li>\n<li><a href=\"\/it\/hgh-191aa\/\"><strong>HGH 191AA<\/strong><\/a> \u2014 Molecola genitore a lunghezza intera \u2014 per farmacologia comparativa con coinvolgimento dell'asse GH<\/li>\n<li><a href=\"\/it\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 Analoghi del GHRH \u2014 stimolazione a monte dell'asse HGH<\/li>\n<li><a href=\"\/it\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH 1-29 analogue \u2014 pituitary endogenous-HGH studies<\/li>\n<li><a href=\"\/it\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrial-derived metabolic peptide \u2014 alternative-mechanism fat-loss studies<\/li>\n<li><a href=\"\/it\/bac-water\/\"><strong>BAC Water (Acqua Batteriostatica)<\/strong><\/a> \u2014 Necessario per ricostituire qualsiasi flaconcino liofilizzato \u2014 diluente sterile, conservato con alcol benzilico 0,9%<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Frammento lipolitico C-terminale hGH 176-191 stabilizzato (estensione N-terminale Tyr)<br \/>\n\u2705 Sviluppato da Metabolic Pharmaceuticals Ltd (Monash University, fine anni '90)<br \/>\n\u2705 GHR-disaccoppiato \u2014 nessun IGF-1, nessun JAK2\/STAT5, nessun coinvolgimento dell'asse della crescita<br \/>\n\u2705 Lipolitico + anti-lipogenico; dipendente da \u03b23-AR (meccanismo non completamente caratterizzato)<br \/>\n\u2705 Emivita plasmatica di ~4 min; studio di Fase IIb sull'obesit\u00e0 fallito (2007); PM 1815.1, CAS 221231-10-3<\/p>\n<p><strong>AOD-9604<\/strong> contains synthetic Tyr-hGH(177-191) peptide.<\/p>","protected":false},"featured_media":71463,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6500,6499,6502,6503,6289,6501,6494],"class_list":["post-71446","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-anti-obesity-drug","product_tag-aod-9604","product_tag-fat-loss-research","product_tag-ghr-decoupled","product_tag-hgh-fragment","product_tag-lipolytic-peptide","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product\/71446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/comments?post=71446"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media\/71463"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media?parent=71446"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_brand?post=71446"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_cat?post=71446"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_tag?post=71446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}